RhumbLine Advisers
SABS icon

RhumbLine Advisers’s SAB Biotherapeutics SABS Stock Holding History

RhumbLine Advisers’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$151K Buy
47,734
+2,570
+6% +$9.35K ﹤0.01% 3382
2026
Q2 		$176K Buy
+45,164
New +$168K ﹤0.01% 3335

Other funds holding SABS

Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Propel Bio Management
Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

RhumbLine Advisers's SABS Position: Q3 2026 in Review

RhumbLine Advisers increased its SAB Biotherapeutics (SABS) stake by 5.7% in Q3 2026, buying an estimated $9.35K and bringing the position to 47,734 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #3382.

RhumbLine Advisers first reported a position in SABS in Q2 2026 and has held it in 2 quarters since. The position peaked at $176K in Q2 2026. 61 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • RhumbLine Advisers held 47,734 shares of SAB Biotherapeutics worth $151K as of Q3 2026.
  • RhumbLine Advisers bought 2,570 SAB Biotherapeutics shares in Q3 2026, an estimated $9.35K.
  • SAB Biotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3382 holding.
  • RhumbLine Advisers first reported a position in SAB Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • RhumbLine Advisers's SAB Biotherapeutics position peaked at $176K in Q2 2026.
  • 61 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.